Literature DB >> 12538729

Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis.

Daniel T Eitzman1, Peter F Bodary, Yuechun Shen, Christian G Khairallah, Susan R Wild, Akira Abe, Jacqueline Shaffer-Hartman, James A Shayman.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder due to deficiency of alpha-galactosidase A (GLA) activity that results in the widespread accumulation of neutral glycosphingolipids. Renal failure, neuropathy, premature myocardial infarction, and stroke occur in patients with this condition primarily due to deposition of glycosphingolipids in vascular endothelial cells. The clinical consequences of Fabry disease suggest that vascular thrombosis may play a prominent role in the pathogenesis of this disease; however, the vasculopathy associated with Fabry disease has not been extensively studied. To determine if mice genetically deficient in Gla are susceptible to vascular thrombosis, a photochemical carotid injury model was used to induce occlusive thrombosis. In this model, Gla-/0 mice displayed a progressive age-dependent shortening of the time to occlusive thrombosis after vascular injury that correlated with progressive accumulation of globotriasylceramide (Gb3) in the arterial wall. Bone marrow transplantation from Gla-/0 to Gla+/0 mice and from Gla+/0 to Gla-/0 mice did not change the thrombotic phenotype of the host. These studies reveal a potent vascular prothrombotic phenotype in Gla-deficient mice and suggest that antithrombotic therapies as well as therapies designed to reduce the vascular accumulation of Gb3 may have beneficial effects on thrombotic complications in patients with Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538729     DOI: 10.1097/01.asn.0000043901.45141.d4

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

2.  Establishment and characterization of an experimental model of coronary thrombotic microembolism in rats.

Authors:  Ye Gu; Yupeng Bai; Jie Wu; Liqun Hu; Bo Gao
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.

Authors:  Atsumi Taguchi; Hiroki Maruyama; Masaaki Nameta; Tadashi Yamamoto; Junichiro Matsuda; Ashok B Kulkarni; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

4.  Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.

Authors:  David F Moore; Monique P Gelderman; Paulo A Ferreira; Steven R Fuhrmann; Haiqing Yi; Abdel Elkahloun; Lisa M Lix; Roscoe O Brady; Raphael Schiffmann; Ehud Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

5.  Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.

Authors:  James L Park; Steven E Whitesall; Louis G D'Alecy; Liming Shu; James A Shayman
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-06-18       Impact factor: 2.557

6.  Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

Authors:  Liming Shu; James L Park; Jaeman Byun; Subramaniam Pennathur; Jessica Kollmeyer; James A Shayman
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

7.  Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

Authors:  Justin J Kang; Liming Shu; James L Park; James A Shayman; Peter F Bodary
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-14       Impact factor: 4.052

8.  High incidence of autoantibodies in Fabry disease patients.

Authors:  P Martinez; M Aggio; P Rozenfeld
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

9.  Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

Authors:  Jin-Song Shen; Xing-Li Meng; David F Moore; Jane M Quirk; James A Shayman; Raphael Schiffmann; Christine R Kaneski
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

10.  Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries.

Authors:  Helena Hůlková; Helena Poupetová; Klaus Harzer; Pramod Mistry; Johannes M F G Aerts; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.